F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery

Biomaterials

Volumn 34, Issue 4, 2013, Pages 1135-1145

  Hu, Quanyin ^a   Gu, Guangzhi ^a   Liu, Zhongyang ^a   Jiang, Mengyin ^d   Kang, Ting ^a   Miao, Deyu ^d   Tu, Yifan ^a   Pang, Zhiqing ^a   Song, Qingxiang ^b   Yao, Lei ^b   Xia, Huimin ^a,c   Chen, Hongzhan ^b   Jiang, Xinguo ^a   Gao, Xiaoling ^b   Chen, Jun ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI INSTITUTE FOR FOOD AND DRUG CONTROL   (China)

^d SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Anti glioma; Co administration; F3 peptide; Nanoparticle; Paclitaxel; TLyp 1 peptide

Indexed keywords

ANTI-GLIOMA; C6 CELLS; CELLULAR INTERACTION; CELLULAR INTERNALIZATION; CO-ADMINISTRATION; COUPLING REACTION; DEEP PENETRATION; FUNCTIONALIZED NANOPARTICLES; GLIOMA CELLS; MULTICELL; NANOPARTICULATE DRUG DELIVERY SYSTEMS; NEOVASCULATURE; NUCLEOLIN; PACLITAXEL; TUMOR SITE; TUMOR SPHEROID; TUMOR TARGETING; VASCULAR EXTRAVASATION; VASCULATURE; XPS ANALYSIS;

BLOOD VESSELS; CHEMOTHERAPY; CYTOLOGY; DRUG DELIVERY; ENDOTHELIAL CELLS; NANOPARTICLES; PEPTIDES;

TUMORS;

NANOPARTICLE; NUCLEOLIN; PACLITAXEL; PEPTIDE; TLYP 1 PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL HOMING; CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; GLIOMA; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIMIT OF DETECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SURVIVAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOMA; MICE; MICE, NUDE; NANOCAPSULES; PACLITAXEL; PEPTIDES; PEPTIDES, CYCLIC; POLYETHYLENE GLYCOLS; RATS; TREATMENT OUTCOME;

MUS;

EID: 84870363825     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.10.048     Document Type: Article

References (49)

1. Wen P.Y., Kesari S. Malignant gliomas in adults. N Engl J Med 2008, 359(5):492-507.
2. Behin A., Hoang-Xuan K., Carpentier A.F., Delattre J.Y. Primary brain tumours in adults. Lancet 2003, 361(9354):323-331.
3. Gladson C.L., Prayson R.A., Liu W.M. The pathobiology of glioma tumors. Annu Rev Pathol 2010, 5:33-50.
4. Roger M., Clavreul A., Venier-Julienne M.C., Passirani C., Montero-Menei C., Menei P. The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials 2011, 32(8):2106-2116.
5. Ren J., Shen S., Wang D., Xi Z., Guo L., Pang Z., et al. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 2012, 33(11):3324-3333.
6. Beduneau A., Saulnier P., Benoit J.P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007, 28(33):4947-4967.
7. Jiang X., Sha X., Xin H., Chen L., Gao X., Wang X., et al. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors. Biomaterials 2011, 32(35):9457-9469.
8. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2(12):751-760.
9. McNeeley K.M., Karathanasis E., Annapragada A.V., Bellamkonda R.V. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials 2009, 30(23-24):3986-3995.
10. Shoichet M.S., Winn S.R. Cell delivery to the central nervous system. Adv Drug Deliv Rev 2000, 42(1-2):81-102.
11. Liu Y., Lu W. Recent advances in brain tumor-targeted nano-drug delivery systems. Expert Opin Drug Deliv 2012, 9(6):671-686.
12. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012, 161(2):175-187.
13. Aktas Y., Yemisci M., Andrieux K., Gursoy R.N., Alonso M.J., Fernandez-Megia E., et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem 2005, 16(6):1503-1511.
14. Xin H., Sha X., Jiang X., Zhang W., Chen L., Fang X. Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials 2012, 33(32):8167-8176.
15. Christian S., Pilch J., Akerman M.E., Porkka K., Laakkonen P., Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003, 163(4):871-878.
16. Porkka K., Laakkonen P., Hoffman J.A., Bernasconi M., Ruoslahti E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci U S A 2002, 99(11):7444-7449.
17. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6(8):583-592.
18. Bhagat M., Halligan S., Sofou S. Nanocarriers to solid tumors: considerations on tumor penetration and exposure of tumor cells to therapeutic agents. Curr Pharm Biotechnol 2012, 13(7):1306-1316.
19. Ruoslahti E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater 2012, 24(28):3747-3756.
20. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Girard O.M., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009, 16(6):510-520.
21. Roth L., Agemy L., Kotamraju V.R., Braun G., Teesalu T., Sugahara K.N., et al. Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene 2012, 31(33):3754-3763.
22. Xia H., Gao X., Gu G., Liu Z., Hu Q., Tu Y., et al. Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery. Int J Pharm 2012, 436(1-2):840-850.
23. Olivier J.C., Huertas R., Lee H.J., Calon F., Pardridge W.M. Synthesis of pegylated immunonanoparticles. Pharm Res 2002, 19(8):1137-1143.
24. Yu D.H., Lu Q., Xie J., Fang C., Chen H.Z. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 2010, 31(8):2278-2292.
25. Han L.M., Guo J., Zhang L.J., Wang Q.S., Fang X.L. Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123. Acta Pharmacol Sin 2006, 27(6):747-753.
26. Xin H., Jiang X., Gu J., Sha X., Chen L., Law K., et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 2011, 32(18):4293-4305.
27. Gao X., Yao L., Song Q., Zhu L., Xia Z., Xia H., et al. The association of autophagy with polyethylenimine-induced cytotoxicity in nephritic and hepatic cell lines. Biomaterials 2011, 32(33):8613-8625.
28. Hirschhaeuser F., Menne H., Dittfeld C., West J., Mueller-Klieser W., Kunz-Schughart L.A. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 2010, 148(1):3-15.
29. Xia H., Gao X., Gu G., Liu Z., Zeng N., Hu Q., et al. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials 2011, 32(36):9888-9898.
30. Guo J., Gao X., Su L., Xia H., Gu G., Pang Z., et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011, 32(31):8010-8020.
31. Zeng N., Hu Q., Liu Z., Gao X., Hu R., Song Q., et al. Preparation and characterization of paclitaxel-loaded DSPE-PEG-liquid crystalline nanoparticles (LCNPs) for improved bioavailability. Int J Pharm 2012, 424(1-2):58-66.
32. Maher E.A., Furnari F.B., Bachoo R.M., Rowitch D.H., Louis D.N., Cavenee W.K., et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001, 15(11):1311-1333.
33. Biddlestone-Thorpe L., Marchi N., Guo K., Ghosh C., Janigro D., Valerie K., et al. Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents. Adv Drug Deliv Rev 2012, 64(7):605-613.
34. Petri B., Bootz A., Khalansky A., Hekmatara T., Muller R., Uhl R., et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Release 2007, 117(1):51-58.
35. Pang Z., Feng L., Hua R., Chen J., Gao H., Pan S., et al. Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol Pharm 2010, 7(6):1995-2005.
36. Zhan C., Wei X., Qian J., Feng L., Zhu J., Lu W. Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo. J Control Release 2012, 160(3):630-636.
37. Huang R., Ke W., Han L., Li J., Liu S., Jiang C. Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration. Biomaterials 2011, 32(9):2399-2406.
38. He H., Li Y., Jia X.R., Du J., Ying X., Lu W.L., et al. PEGylated poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials 2011, 32(2):478-487.
39. Liu S., Guo Y., Huang R., Li J., Huang S., Kuang Y., et al. Gene and doxorubicin co-delivery system for targeting therapy of glioma. Biomaterials 2012, 33(19):4907-4916.
40. Gerstner E.R., Batchelor T.T. Antiangiogenic therapy for glioblastoma. Cancer J 2012, 18(1):45-50.
41. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5(4):505-515.
42. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3(1):16-20.
43. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011, 63(3):131-135.
44. Jiang X., Xin H., Sha X., Gu J., Jiang Y., Law K., et al. PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation. Int J Pharm 2011, 420(2):385-394.
45. Song Q., Yao L., Huang M., Hu Q., Lu Q., Wu B., et al. Mechanisms of transcellular transport of wheat germ agglutinin-functionalized polymeric nanoparticles in Caco-2 cells. Biomaterials 2012, 33(28):6769-6782.
46. Brown D.A., London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 1998, 14:111-136.
47. McMahon K.M., Volpato M., Chi H.Y., Musiwaro P., Poterlowicz K., Peng Y., et al. Characterization of changes in the proteome in different regions of 3D multicell tumor spheroids. J Proteome Res 2012, 11(5):2863-2875.
48. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65(1-2):271-284.
49. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Greenwald D.R., et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010, 328(5981):1031-1035.